-
1.发明公开HUMAN ANTI-NGF NEUTRALIZING ANTIBODIES AS SELECTIVE NGF PATHWAY INHIBITORS 审中-公开人类抗NGF中和抗体作为选择性NGF途径抑制剂
公开(公告)号：EP3028717A1
公开(公告)日：2016-06-08
申请号：EP15188795.7
申请日：2010-10-08
发明人： WILD, Kenneth D. , TREANOR, James J.s. , HUANG, Haichun , INOUE, Heather , ZHANG, Tie J. , MARTIN, Frank
IPC分类号： A61K39/395 , C07K16/22 , G01N33/53 , C12N15/68 , C12N5/10 , A61P25/00 , A61P35/00 , A61P19/02 , A61P29/02
CPC分类号： C07K16/22 , A61K39/00 , A61K39/3955 , A61K2039/505 , A61K2039/54 , C07K2317/21 , C07K2317/56 , C07K2317/76
摘要： This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
摘要翻译： 本发明提供了与人神经生长因子（NGF）相互作用或结合的抗体，并由此中和NGF的功能。 本发明还提供了所述抗体的药物组合物和通过施用药学有效量的抗NGF抗体来中和NGF功能，特别是用于治疗NGF相关病症（例如慢性疼痛）的方法。 还提供了使用抗NGF抗体检测样品中NGF量的方法。
-
2.发明公开HUMAN ANTI-NGF NEUTRALIZING ANTIBODIES AS SELECTIVE NGF PATHWAY INHIBITORS 有权MENSCHLICHE抗NGF-NEUTRALISIERENDEANTIKÖRPERALS SELEKTIVE缝边德NGF-SIGNALWEGES
公开(公告)号：EP2485760A1
公开(公告)日：2012-08-15
申请号：EP10766193.6
申请日：2010-10-08
申请人： Amgen, Inc , Medarex, Inc.
发明人： WILD, Kenneth, D. , TREANOR, James, J.s. , HUANG, Haichun , INOUE, Heather , ZHANG, Tie, J. , MARTIN, Frank
IPC分类号： A61K39/395 , C07K16/22 , G01N33/53 , C12N15/68 , C12N5/10 , A61P25/00 , A61P35/00 , A61P19/02 , A61P29/02
CPC分类号： C07K16/22 , A61K39/00 , A61K39/3955 , A61K2039/505 , A61K2039/54 , C07K2317/21 , C07K2317/56 , C07K2317/76
摘要： This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
-
公开(公告)号：EP3020414B1
公开(公告)日：2018-10-24
申请号：EP15190744.1
申请日：2003-09-05
发明人： HUANG, Haichun , VARNUM, Brian , VEZINA, Chris , WITTE, Alison , QIAN, Xueming , MARTIN, Frank , ELLIOTT, Gary
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
-
4.发明授权HUMAN ANTI-NGF NEUTRALIZING ANTIBODIES AS SELECTIVE NGF PATHWAY INHIBITORS 有权人抗NGF中和抗体NGF信号路径的选择性抑制剂
公开(公告)号：EP2485760B1
公开(公告)日：2016-07-13
申请号：EP10766193.6
申请日：2010-10-08
发明人： WILD, Kenneth, D. , TREANOR, James, J.s. , HUANG, Haichun , INOUE, Heather , ZHANG, Tie, J. , MARTIN, Frank
IPC分类号： A61K39/395 , C07K16/22 , G01N33/53 , C12N15/68 , C12N5/10 , A61P25/00 , A61P35/00 , A61P19/02 , A61P29/02
CPC分类号： C07K16/22 , A61K39/00 , A61K39/3955 , A61K2039/505 , A61K2039/54 , C07K2317/21 , C07K2317/56 , C07K2317/76
-
公开(公告)号：EP1572946B1
公开(公告)日：2012-03-14
申请号：EP03752058.2
申请日：2003-09-05
申请人： Amgen, Inc. , Medarex, Inc.
发明人： VARNUM, Brian , VEZINA, Chris , WITTE, Alison , QIAN, Xueming , MARTIN, Frank , HUANG, Haichun , ELLIOTT, Gary
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
-
6.发明授权HUMAN ANTI-NGF NEUTRALIZING ANTIBODIES AS SELECTIVE NGF PATHWAY INHIBITORS 有权人类抗NGF中和抗体作为选择性NGF途径抑制剂
公开(公告)号：EP1648509B8
公开(公告)日：2012-10-24
申请号：EP04778409.5
申请日：2004-07-15
申请人： Amgen Inc. , Medarex, Inc.
发明人： WILD, Kenneth, D., Jr. , TREANOR, James, J., S. , HUANG, Haichun , INOUE, Heather , ZHANG, Tie, J. , MARTIN, Frank
CPC分类号： C07K16/22 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , G01N33/74 , G01N2333/48 , G01N2800/2842
摘要： This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
-
公开(公告)号：EP1572946A2
公开(公告)日：2005-09-14
申请号：EP03752058.2
申请日：2003-09-05
申请人： Amgen, Inc.
发明人： VARNUM, Brian , VEZINA, Chris , WITTE, Alison , QIAN, Xueming , MARTIN, Frank , HUANG, Haichun , ELLIOTT, Gary
IPC分类号： C12N1/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
-
公开(公告)号：EP3020414A1
公开(公告)日：2016-05-18
申请号：EP15190744.1
申请日：2003-09-05
发明人： HUANG, Haichun , VARNUM, Brian , VEZINA, Chris , WITTE, Alison , QIAN, Xueming , MARTIN, Frank , ELLIOTT, Gary
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
摘要翻译： 描述了与白细胞介素-1受体1型（IL-1R1）相互作用的抗体。 描述了通过向IL-1R1施用药学有效量的抗体来治疗IL-1介导的疾病的方法。 描述了使用IL-1R1抗体检测样品中IL-1R1的量的方法。
-
9.发明授权
公开(公告)号：EP1648509B1
公开(公告)日：2012-09-12
申请号：EP04778409.5
申请日：2004-07-15
申请人： Amgen Inc. , Medarex, Inc.
发明人： WILD, Kenneth, D., Jr. , TREANOR, James, J., S. , HUANG, Haichun , INOUE, Heather , ZHANG, Tie, J. , MARTIN, Frank
CPC分类号： C07K16/22 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , G01N33/74 , G01N2333/48 , G01N2800/2842
摘要： This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
-
10.发明公开HUMAN ANTI-NGF NEUTRALIZING ANTIBODIES AS SELECTIVE NGF PATHWAY INHIBITORS 有权人文抗NGF NEUTRALISIERENDEANTIKÖRPERALS SELEKTIVE NGF，缝边
公开(公告)号：EP1648509A2
公开(公告)日：2006-04-26
申请号：EP04778409.5
申请日：2004-07-15
申请人： Amgen Inc.
发明人： WILD, Kenneth, D., Jr. , TREANOR, James, J., S. , HUANG, Haichun , INOUE, Heather , ZHANG, Tie, J. , MARTIN, Frank
CPC分类号： C07K16/22 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , G01N33/74 , G01N2333/48 , G01N2800/2842
摘要： This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.018 秒)
